The Leaf THE LEAF March-April 2019 | Page 30

State legislatures are following suit; medical cannabis is legal in 23 states and the District of Columbia, and more than a dozen other states allow some patients access to certain potency levels of the drug if a physician documents that it’s medically necessary, or if the sick person has exhausted other options. A large number of these patients have cancer, and many who gain access to medical marijuana report that it works. “A day doesn’t go by where I don’t see a cancer patient who has nausea, vomiting, loss of appetite, pain, depression and insomnia,” says Dr. Donald Abrams, chief of haematology-oncology at San Francisco General Hospital and a professor of clinical medicine at the University of California, San Francisco. Marijuana, he says, “is the only anti-nausea medicine that increases appetite.” It also helps patients sleep and elevates their mood—no easy feat when someone is facing a life-threatening illness. “I could write six different prescriptions, all of which may interact with each other or the chemotherapy that the patient has been prescribed. Or I could just recommend trying one medicine,” Abrams says. A 2014 poll conducted by Medscape and WebMD found that more than three-quarters of U.S. physicians think cannabis provides real therapeutic benefits. And those working with cancer patients were the strongest supporters: 82 percent of oncologists agreed that cannabis should be offered as a treatment option. Dr. Benjamin Kligler, associate professor of family and social medicine at Albert Einstein College of Medicine, says there has been enough research to prove that at a bare minimum cannabis won’t actually harm a person. In addition, “given what we've seen anecdotally in practice I think there's no reason we shouldn't see more integration of cannabis in the long run as a strategy,” he says. “We have this extremely safe, extremely useful medicine that could potentially benefit a huge population.” Some years ago, Dr. Gil Bar-Sela, director of the integrated oncology and palliative care unit at the Rambam Health Care Campus in Haifa, Israel conducted two rounds of phone interviews with 131 cancer patients who used cannabis while in chemotherapy; just less than 4 percent of participants reported that they experienced a worsening of symptoms when they started using cannabis and the majority said it helped, according to the resulting paper published, in Evidence-Based Complementary and Alternative Medicine in 2013. But self-reported data like this is limited when it comes to proving the clinical impact of cannabis. Patients may be biased in their opinions that cannabis is effective, may not accurately document their use of the drug, or may confuse the effects with those of the cancer treatment. In addition, symptoms such as pain are subjective and difficult for a physician to measure. A paper published recently in JAMA analysed the findings of 79 studies on cannabinoids for a variety of indications, including nausea and vomiting from chemotherapy, appetite stimulation for patients with HIV/AIDS, chronic pain and multiple sclerosis, among other conditions. This review, which accounted for 6,462 patients, found most who used cannabinoids reported improvements to symptoms compared with patients in placebo groups. However, the researchers say these improvements were not statistically significant. The analysis also indicated that cannabinoids had limited impact on symptoms of nausea and vomiting, and a number of patients reported adverse effects from the drug, including dizziness, disorientation, confusion and hallucinations.